Enzon Pharmaceuticals Announces 1-for-100 Reverse Stock Split Ahead of Merger with Viskase Companies

Key Highlights

• Reverse Stock Split: Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) has announced the implementation of a previously approved 1-for-100 reverse stock split, effective March 24, 2026, at 4:30 pm Eastern Time. Trading on a split-adjusted basis is expected to commence on March 25, 2026, under the temporary ticker symbol “ENZND” for 20 trading days.
• Share Consolidation: Every 100 shares of Enzon common stock will be consolidated into 1 share. The par value per share will remain unchanged. Stockholders will not receive fractional shares; instead, cash payments proportional to fractional entitlements will be issued.
• Exchange Agent: Continental Stock Transfer & Trust will handle the exchange process. Shareholders holding shares electronically or in brokerage accounts are not required to take any action; their shareholdings will be adjusted automatically.
• Merger Preparations: The reverse stock split is a strategic move to facilitate the anticipated merger with Viskase Companies, Inc. It also supports the planned exchange offer of Enzon’s Series C Non-Convertible Redeemable Preferred Stock for common shares.
• Exchange Offer: The exchange offer is scheduled to expire at 5:00 pm Eastern Time on March 24, 2026, with the merger’s closing expected shortly after. Terms and details are provided in filings with the SEC.
• Forward-Looking Statements and Risks: The company has outlined numerous risks and uncertainties related to the merger, including regulatory approvals, timing, integration, financial results, potential litigation, and market reactions.

Detailed Analysis for Investors

Enzon Pharmaceuticals’ announcement of a 1-for-100 reverse stock split is a major corporate action, designed to position the company for the closing of its merger with Viskase Companies, Inc., and to facilitate the exchange of preferred shares for common shares. The reverse split will significantly reduce the number of outstanding shares, potentially impacting share price, trading liquidity, and future corporate actions.

Shareholder Impact: Existing shareholders should be aware that their holdings will be consolidated, with 100 shares becoming 1. This reduction in outstanding shares could increase the per-share price, but does not change the total value held, except for those entitled to fractional shares, who will receive cash compensation.

The temporary change in ticker symbol to “ENZND” may affect visibility and trading patterns for a short period (20 trading days). No action is required by shareholders, as the transfer agent and brokerage systems will handle the adjustments automatically.

Merger and Exchange Offer: The reverse stock split is directly tied to the anticipated merger with Viskase Companies, Inc. This strategic transaction is expected to be completed soon after the exchange offer expires. The merger and exchange offer are pivotal events that could materially affect the company’s future direction, operations, and valuation. The exchange offer allows holders of Series C Non-Convertible Redeemable Preferred Stock to convert their holdings to common stock, potentially increasing the common equity base and changing the ownership structure.

Risks and Uncertainties: Investors should note extensive forward-looking statements and risk disclosures. Key risks include:

• Possible failure to obtain regulatory or shareholder approval for the merger.
• Uncertainty about the timing and completion of the merger and exchange offer.
• Integration challenges and financial impacts post-merger, including revenue, expenses, and operational synergies.
• Potential litigation related to the merger.
• Disruption to existing business relationships and operational uncertainty during the transition period.
• Possible changes in ownership levels and exchange ratio following the merger.
• External risks such as geopolitical events, legislative changes, and macroeconomic factors.

These risks could affect share price volatility and investor confidence.

Why This News Is Price Sensitive

The reverse stock split, merger plans, and exchange offer represent significant corporate restructuring events. These actions may result in substantial changes to Enzon’s capital structure, share price, and future business prospects. Investors should closely monitor developments, as successful completion of the merger and exchange offer could unlock new growth opportunities, while any delays or failures may negatively impact share value.

Company Background

Enzon Pharmaceuticals, Inc., together with its subsidiary, operates as a public company acquisition vehicle, seeking to become an acquisition platform.

Contact Information

For media inquiries, contact Richard L. Feinstein, CEO and CFO at [email protected].

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should review official filings and consult their financial advisors before making any investment decisions. All forward-looking statements are subject to risks and uncertainties as described by Enzon Pharmaceuticals, Inc. and Viskase Companies, Inc. in their SEC filings.

View ENZON PHARMACEUTICALS, INC. Historical chart here